Skip to main
SGHT
SGHT logo

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 29%
Buy 0%
Hold 57%
Sell 14%
Strong Sell 0%

Bulls say

Sight Sciences Inc has demonstrated a robust financial performance with a gross margin of 86.8%, exceeding consensus expectations and reflecting a 160 basis point year-over-year increase. The company experienced a 3% quarter-over-quarter increase in ordering facilities, reaching a total of 1,138, indicating strengthened market penetration. Furthermore, the anticipated revenue growth, driven by accelerated market share gains in minimally invasive glaucoma surgery (MIGS) and the quicker adoption of the TearCare System, suggests promising potential for future profitability.

Bears say

Sight Sciences Inc. experienced significant challenges in its financial performance, particularly within its Dry Eye segment, which reported revenue of $0.3 million, missing consensus estimates and reflecting an 81.0% growth but still indicative of underlying difficulties given a decline from previous periods. The company's revised GAAP EPS estimates for 2025 and 2026 have been significantly lowered, highlighting worsening profitability expectations amid anticipated revenue declines starting in the first quarter of 2025. Additionally, the impact of recently implemented Local Coverage Determinations (LCDs) has been noted to negatively influence OMNI volumes, contributing to a broader outlook of slowing revenue growth due to reimbursement headwinds.

Sight Sciences (SGHT) has been analyzed by 7 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 0% recommend Buy, 57% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Hold based on their latest research and market trends.

According to 7 analysts, Sight Sciences (SGHT) has a Hold consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.